1364677-75-7

Upstream product

• 374-01-6 (S)-1,1,1-trifluoro-2-propanol 
• 1364677-73-5 5-chloro-3-(4-chloro-phenyl)-2-fluoro-pyridine 
• 1679-18-1 4-Chlorophenylboronic acid 
• 884494-87-5 3-bromo-5-chloro-2-fluoropyridine 

Downstream Products

• 1364677-77-9 (S)-methyl 5-(4-chlorophenyl)-6-(1,1,1-trifluoropropan-2-yloxy)nicotinate 
• 1372606-94-4 [5-(4-Chloro-phenyl)-6-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-3-yl]-carbamic acid tert-butyl ester 
• 1372605-69-0 (S)-N-(5-(4-chlorophenyl)-6-(1,1,1-trifluoropropan-2-yloxy)pyridin-3-yl)pyridazine-3-carboxamide 
• 1372606-96-6 5-(4-chloro-phenyl)-6-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyridin-3-ylamine 

Relevant academic research and scientific papers

N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES

The present invention relates to compounds of formula I, wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof. The present invention also relates to the manufacture of such compounds or

N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES

The present invention relates to compounds of the formula I wherein A, R1 to R7 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and thei

HETEROARYLMETHYL AMIDES

The present invention relates to compounds of the formula wherein A1, A2, A3 and R1 to R8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

HETEROARYLMETHYL AMIDES

The present invention relates to compounds of the formula I wherein A1, A2, A3 and R1 to R8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.